Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ATB-346 in Healthy Subjects
NCT03220633Phase 1Completed
- Sponsor
- Antibe Therapeutics Inc.
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic pain comparing ATB-346 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 weeks. Started Jun 2014; status: completed.
02
Drugs
otenaproxesul
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT03220633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220633.